BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 34331598)

  • 21. Plasma Extracellular Vesicle-Derived TIMP-1 mRNA as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Pilot Study.
    Dias F; Teixeira AL; Nogueira I; Morais M; Maia J; Bodo C; Ferreira M; Vieira I; Silva J; Lobo J; Sequeira JP; Maurício J; Oliveira J; Palmeira C; Martins G; Kok K; Costa-Silva B; Medeiros R
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32610589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
    Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
    Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.
    Schrödter S; Braun M; Syring I; Klümper N; Deng M; Schmidt D; Perner S; Müller SC; Ellinger J
    Mol Cancer; 2016 Feb; 15():10. PubMed ID: 26831905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer.
    Chandarana H; Rosenkrantz AB; Mussi TC; Kim S; Ahmad AA; Raj SD; McMenamy J; Melamed J; Babb JS; Kiefer B; Kiraly AP
    Radiology; 2012 Dec; 265(3):790-8. PubMed ID: 23175544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum extracellular vesicles contain SPARC and LRG1 as biomarkers of colon cancer and differ by tumour primary location.
    Zhong ME; Chen Y; Xiao Y; Xu L; Zhang G; Lu J; Qiu H; Ge W; Wu B
    EBioMedicine; 2019 Dec; 50():211-223. PubMed ID: 31753726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
    Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
    Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
    Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
    Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
    Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
    Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening and identification of key biomarkers of papillary renal cell carcinoma by bioinformatic analysis.
    Xu Y; Kong D; Li Z; Qian L; Li J; Zou C
    PLoS One; 2021; 16(8):e0254868. PubMed ID: 34358255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
    Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
    J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
    Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
    Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
    Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
    Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracellular Vesicles and Carried miRNAs in the Progression of Renal Cell Carcinoma.
    Grange C; Brossa A; Bussolati B
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomorphologic analysis of clear cell papillary renal cell carcinoma: Distinguishing diagnostic features.
    Griffin BB; Lin X
    Cancer Cytopathol; 2021 Mar; 129(3):192-203. PubMed ID: 33036062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
    Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
    Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
    DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells.
    Doberstein K; Wieland A; Lee SB; Blaheta RA; Wedel S; Moch H; Schraml P; Pfeilschifter J; Kristiansen G; Gutwein P
    Carcinogenesis; 2011 Mar; 32(3):262-70. PubMed ID: 21097529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-induced microRNA-155 overexpression in extracellular vesicles promotes renal cell carcinoma progression by targeting
    Meng L; Xing Z; Guo Z; Qiu Y; Liu Z
    Aging (Albany NY); 2021 Mar; 13(7):9613-9626. PubMed ID: 33742606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
    Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
    Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
    Linehan WM; Ricketts CJ
    Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.